506 related articles for article (PubMed ID: 32071145)
1. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
4. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
5. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
8. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs.
Guo Z; Stiller JW
BMC Genomics; 2004 Sep; 5():69. PubMed ID: 15380029
[TBL] [Abstract][Full Text] [Related]
9. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
[TBL] [Abstract][Full Text] [Related]
12. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract][Full Text] [Related]
15. Cell Cycle Regulation in Treatment of Breast Cancer.
Cai Z; Liu Q
Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
17. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
[TBL] [Abstract][Full Text] [Related]
18. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase pathways as targets for cancer treatment.
Shapiro GI
J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
[TBL] [Abstract][Full Text] [Related]
20. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]